Evidence map›Paper›PMID 23277550›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2013

Molecular dissection of dystrophin identifies the docking site for nNOS.

Scott Q Harper

Registry-linked trialAbstract readComment
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06290713 (Vasodilators and Exercise as Adjuvant Therapy for Duchenne Muscular Dystrophy), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06290713 phase2recruitingnot on this mapstarted 2024, after this paper: background citation

Vasodilators and Exercise as Adjuvant Therapy for Duchenne Muscular Dystrophy (VASO-REx Study)

TypeinterventionalSponsorUniversity of FloridaRan2024 to 2026Enrolled50ConditionsDuchenne Muscular Dystrophy, Duchenne Disease, Muscular Dystrophy, Muscular Dystrophy in ChildrenArmsTadalafil, Placebo, Exercise Training
3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy.Molecular therapy : the journal of the American Society of Gene Therapy · 2018
    Review
  4. Article
  5. Nanotherapy for Duchenne muscular dystrophy.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2018
    Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Scott Q HarperDepartment of Pediatrics, Ohio State University College of Medicine and Center for Gene Therapy, Research Institute at Nationwide Children's Hospital, Columbus, OH 43205, USA. scott.harper@nationwidechildrens.org

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Protein Structure, SecondaryAnimalsCell MembraneDystrophinMuscular Dystrophy, DuchenneNeuronsNitric Oxide Synthase Type IDystrophinNitric Oxide Synthase Type I

Identifiers

PMID23277550
PMCPMC3545786

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.